These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6905865)

  • 21. Compliance with Good Manufacturing Practices for facilities engaged in vector production, cell isolation, and genetic manipulations.
    Steel MP; Roessler BJ
    Curr Opin Biotechnol; 1999 Jun; 10(3):295-7. PubMed ID: 10361080
    [No Abstract]   [Full Text] [Related]  

  • 22. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 25. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of biologics by food animal practitioners.
    Herrick JB
    J Am Vet Med Assoc; 1990 Jun; 196(12):1937. PubMed ID: 2365615
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agreed minutes; meeting between the Food and Drug Administration and the Health Authorities of Switzerland. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Jun; 64(107):30038-40. PubMed ID: 10558562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to comply with the Food and Drug Administration's "Investigational Device Exemption (IDE)" regulations including an application form (revised January 1982).
    Artif Organs; 1982 Feb; 6(1):91-118. PubMed ID: 7073530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parenteral manufacturing and legal regulations.
    Tamura LK
    Bull Parenter Drug Assoc; 1968; 22(6):261-6. PubMed ID: 5727161
    [No Abstract]   [Full Text] [Related]  

  • 32. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 33. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Regulation of biological products".
    Fehnel PO
    Proc Inst Med Chic; 1972 Nov; 29(6):220. PubMed ID: 4678553
    [No Abstract]   [Full Text] [Related]  

  • 35. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 36. Removal of Review and Reclassification Procedures for Biological Products Licensed Prior to July 1, 1972. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Feb; 81(29):7445-6. PubMed ID: 26878738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons learned from good manufacturing practice noncompliance.
    Peskoe MP
    Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
    [No Abstract]   [Full Text] [Related]  

  • 38. "Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(44):11023-4. PubMed ID: 10557623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 40. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.